Will long-lasting HIV preventive be a game changer—or a missed opportunity?
FDA’s approval of lenacapavir comes at a time when global health cuts could stall its rollout
FDA’s approval of lenacapavir comes at a time when global health cuts could stall its rollout
Nearly eradicated in the late 1990s, the STD is now as bad as it was in 1950.
Though the health and human services secretary has been avid fan of raw milk, he hasn’t pushed for changes to federal policies — yet.
At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to…
Injections of mRNA may offer a simpler, cheaper way to build powerful CAR-T cells
Little Remedies® Honey Cough Syrup was voluntarily recalled due to the presence of Bacillus cereus, which can cause two types of food-borne illnesses, and loss…
On this week’s show: Visiting the Vera C. Rubin Observatory, and the impact of plastic bag regulations on reductions in marine litter
At ASM Microbe 2025, researchers underscore the role of NAAT in outpatient CDI diagnosis and raise concerns over PPI-related risk in older, healthcare-associated cases.
Developing lenacapavir, the drug newly approved to protect against HIV for six months in one shot, took basic science, sophisticated chemistry, and perseverance
The Kigali Call to Action is a global rallying cry to protect hard-won progress in the fight against HIV. Launched during IAS 2025, it highlights…
There are many ways to get tested for HIV. Your HIV testing experience might differ depending on where you get tested and th…